Last reviewed · How we verify
Dicycloplatin (TP21)
Dicycloplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to inhibit cancer cell proliferation.
Dicycloplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to inhibit cancer cell proliferation. Used for Advanced or metastatic solid tumors (Phase 3 development).
At a glance
| Generic name | Dicycloplatin (TP21) |
|---|---|
| Sponsor | Gao-jun Teng |
| Drug class | Platinum-based chemotherapy agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
As a third-generation platinum compound, dicycloplatin binds to DNA and forms interstrand and intrastrand crosslinks, preventing DNA replication and transcription in cancer cells. This leads to cell cycle arrest and apoptosis. The drug is designed to have improved efficacy and potentially reduced nephrotoxicity compared to earlier platinum agents like cisplatin.
Approved indications
- Advanced or metastatic solid tumors (Phase 3 development)
Common side effects
- Nephrotoxicity
- Ototoxicity
- Myelosuppression
- Nausea and vomiting
- Peripheral neuropathy
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dicycloplatin (TP21) CI brief — competitive landscape report
- Dicycloplatin (TP21) updates RSS · CI watch RSS
- Gao-jun Teng portfolio CI